CRIS Current Research Information System

DE BENEDITTIS, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.398
EU - Europa 2.220
AS - Asia 1.345
AF - Africa 178
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 7.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.390
GB - Regno Unito 686
CN - Cina 474
IT - Italia 374
SE - Svezia 359
SG - Singapore 326
VN - Vietnam 291
DE - Germania 285
IN - India 155
IE - Irlanda 112
RU - Federazione Russa 93
FR - Francia 84
TG - Togo 80
EE - Estonia 58
ZA - Sudafrica 56
UA - Ucraina 42
JO - Giordania 41
BG - Bulgaria 37
CH - Svizzera 25
CI - Costa d'Avorio 21
NG - Nigeria 20
FI - Finlandia 16
BE - Belgio 15
PL - Polonia 10
IR - Iran 9
JP - Giappone 9
BR - Brasile 7
CA - Canada 7
LB - Libano 7
NL - Olanda 7
TR - Turchia 6
KR - Corea 5
AU - Australia 4
CZ - Repubblica Ceca 4
EU - Europa 4
GR - Grecia 4
HK - Hong Kong 4
HR - Croazia 4
ID - Indonesia 4
QA - Qatar 4
UZ - Uzbekistan 4
CL - Cile 3
NO - Norvegia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BD - Bangladesh 1
BO - Bolivia 1
CO - Colombia 1
EG - Egitto 1
IL - Israele 1
IQ - Iraq 1
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 7.162
Salva come PNG Salva come JPEG
Città #
Southend 648
Fairfield 431
Chandler 416
Singapore 290
Ashburn 241
Houston 210
Dong Ket 195
Wilmington 194
Woodbridge 189
Seattle 187
Princeton 152
Cambridge 139
Dublin 112
Ann Arbor 104
Bologna 102
Santa Clara 84
Lomé 80
Boardman 78
Nanjing 65
Beijing 63
Westminster 62
Padova 52
New York 43
Amman 41
Medford 40
Sofia 37
Redmond 33
Bremen 30
Berlin 28
Jinan 28
San Diego 28
Turin 28
Shenyang 26
Changsha 25
Hebei 24
Saint Petersburg 24
Abidjan 21
Abeokuta 20
Bern 20
Jiaxing 20
Nanchang 20
Florence 16
Helsinki 16
Brussels 15
Milan 15
Norwalk 15
Mountain View 14
Redwood City 14
Guangzhou 13
Tianjin 13
Haikou 11
Olalla 10
Phoenix 10
Dearborn 9
Zhengzhou 9
Des Moines 8
Forlì 8
Fuzhou 7
Kraków 7
Falls Church 6
Hangzhou 6
Los Angeles 6
Ningbo 6
Taizhou 6
Wuhan 6
Bareggio 5
Shanghai 5
Tappahannock 5
Bühl 4
Chengdu 4
Doha 4
Faenza 4
Foshan 4
Hefei 4
Jakarta 4
Kunming 4
Lanzhou 4
Paris 4
São Paulo 4
Andover 3
Chicago 3
Costa Mesa 3
Frankfurt am Main 3
Fremont 3
Gilze 3
Harbin 3
Henderson 3
Istanbul 3
London 3
Monza 3
Portland 3
Qingdao 3
Suzhou 3
Toronto 3
Ulan-ude 3
Wenzhou 3
Wolverhampton 3
Xi'an 3
Zanjan 3
Bengaluru 2
Totale 4.997
Salva come PNG Salva come JPEG
Nome #
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 210
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 188
Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function 165
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 157
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 148
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 137
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 137
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 134
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 133
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 130
Best practices in chronic myeloid leukemia monitoring and management 129
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 128
The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 123
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 118
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 117
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 114
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 114
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 112
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 112
Outcomes following percutaneous treatment of biliary stones 112
Classification performance for covid patient prognosis from automatic ai segmentation—a single-center study 111
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 110
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 110
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 108
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 108
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 107
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 107
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 104
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 104
Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation 104
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 103
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 102
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 102
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 101
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 100
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 100
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 99
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 99
Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation 99
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 98
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 97
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 96
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 92
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients 92
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 90
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 90
Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement 89
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 89
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 89
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 88
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 88
Portal Hypertensive Biliopathy in Adult Patients: Findings and Interventional Radiologic Treatment--A Single-Center Experience 88
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 87
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 87
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 87
Percutaneous abdomino-pelvic abscess drainage in complicated Crohn’s disease 87
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 85
Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage 84
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor 82
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 82
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 81
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 79
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case 78
Present and future of molecular monitoring in chronic myeloid leukaemia. 78
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase 76
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 75
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 75
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 71
Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients Suspected of Having COVID-19 Infection: An Italian Single-Center Experience 68
Percutaneous management of postoperative Bile leak after hepato-pancreato-biliary surgery: a multi-center experience 64
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 61
Totale 7.369
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.338
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.338
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.074 0 0 0 0 0 150 224 181 221 106 104 88
2020/2021984 172 51 21 19 22 55 29 35 123 59 46 352
2021/20221.360 122 27 73 94 131 79 16 108 73 83 304 250
2022/20231.579 165 245 70 215 117 116 55 100 295 29 120 52
2023/2024367 19 74 19 30 31 98 14 10 28 10 9 25
2024/2025756 64 218 141 97 191 45 0 0 0 0 0 0
Totale 7.369